Imperial College London


Faculty of MedicineSchool of Public Health

Deputy Operations Manager







Stadium House, 68 Wood LaneStadium HouseWhite City Campus





Dr Thiagarajah Sasikaran (Sasi) works as one of the Operations Managers in the division of Surgery within the UKCRC-registered Imperial Clinical Trials Unit (ICTU). He joined Imperial College in 2002 and has extensive experience in the delivery of large-scale, multi-centre, international clinical trials. His main interest remains focused on innovative trial design and delivery, to enable key questions to be answered quickly and robustly. Adaptive trial designs include multi-arm, multi-stage RCTs (MAMS) and Trials WithIn Cohorts (TWICS).

Sasi currently oversees the full trial management process for the Imperial Prostate (IP) portfolio of studies including ATLAS (Approaches To Long-Term Active Surveillance), PACIFIC (Prostate Assessment using Comparative Interventions – Fast mri and Image-fusion for Cancer), ATLANTA (Additional Treatments to the Local tumour for metastatic prostate cancer: Assessment of Novel Treatment Algorithms), from applying for funding through to reporting of results.

He has previously managed and delivered numerous multi-centre randomised clinical trials listed below: EMBIO (Left gastric artery embolisation (LGAE) for weight loss in patients with BMI 35-50 kg/m2), CHRONOS (Comparative Health Research Outcomes of Novel Surgery in prostate cancer), AVATAR- AF trial (Ablation Versus Anti-arrhythmic Therapy for reducing All hospital episodes from Recurrent Atrial Fibrillation), SERCA-LVAD trial (Investigation of the safety and feasibility of SERCA2a gene transfer in patients with chronic heart failure and a left ventricular assist device), AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of Ace-inhibition on RisK), FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 inhibition in subjects with Elevated Risks), CVLPRI-t trial (Complete Versus Lesion-only PRimary PCI Pilot) and PILL Pilot (A randomised placebo-controlled trial of fixed-dose combination medication in people at raised risk of cardiovascular disease).



Moss JWE, Todd D, Grodzicki L, et al., 2024, An economic evaluation of a streamlined day-case atrial fibrillation ablation protocol and conventional cryoballoon ablation versus antiarrhythmic drugs in a UK paroxysmal atrial fibrillation population., Pharmacoeconomics - Open, ISSN:2509-4254

Patel P, Thomas R, Hamady M, et al., 2023, EMBIO trial study protocol: left gastric artery embolisation for weight loss in patients living with obesity with a BMI 35-50 kg/m², Bmj Open, Vol:13, ISSN:2044-6055

Kanagaratnam P, McCready J, Tayebjee M, et al., 2023, Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation: a prospective, randomized, multi-centre, open label trial, Ep Europace, Vol:25, ISSN:1099-5129, Pages:863-872


Bass EJ, Fiorentino F, Szigeti M, et al., 2023, Novel trial designs in localised prostate cancer: Pilot phase results from the prostate pathway embedded comparative trial (ip3-prospect), ELSEVIER, Pages:S742-S743, ISSN:0302-2838

Bass EJ, Klimowska-Nassar N, Sasikaran T, et al., 2022, PROState pathway embedded comparative trial: An update to the IP3-PROSPECT study, ELSEVIER, Pages:S506-S506, ISSN:0302-2838

More Publications